Atlas Trials

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Clinical trial NCT04225676 · TERMINATED

Trial details

NCT number
NCT04225676
Sponsor
Novartis Pharmaceuticals
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Acute Lymphoblastic Leukemia
Start date
2020-10-19
Primary completion
2021-10-19
Enrollment
5

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.